John Dieck, MD
Cardiovascular Disease · Austin, TXNPI 1427059310
Payments from drug & device makers
Across 306 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$941
- Abiomed$661
- Actelion Pharmaceuticals US, Inc.$570
- Novartis$514
- Pfizer$422
- Impulse Dynamics (USA) Inc.$302
- plus $2K from 29 others
What the payments were for
- Consulting fees$2003%
- Food & beverage$5,52196%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 26 | $941 |
| Abiomed | 31 | $661 |
| Actelion Pharmaceuticals US, Inc. | 51 | $570 |
| Novartis | 47 | $514 |
| Pfizer | 33 | $422 |
| Impulse Dynamics (USA) Inc. | 8 | $302 |
| E.r. Squibb & Sons, L.L.C. | 18 | $275 |
| Amgen | 15 | $224 |
| Merck | 12 | $210 |
| Bayer | 1 | $200 |
| Intuitive Surgical | 2 | $187 |
| Vifor Pharma, Inc. | 11 | $172 |
| Sanofi-aventis U.S. LLC | 7 | $125 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $110 |
| Johnson & Johnson | 5 | $107 |
| Novo Nordisk | 4 | $81 |
| Cvrx, Inc. | 4 | $76 |
| AstraZeneca | 4 | $75 |
| Cardiva Medical, Inc. | 1 | $75 |
| Boston Scientific | 3 | $70 |
| Siemens Medical Solutions USA, Inc. | 2 | $50 |
| Amarin Pharma, Inc. | 2 | $43 |
| Spinal Simplicity, LLC | 1 | $33 |
| Acist Medical Systems, Inc. | 2 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Cordis US CORP. | 1 | $22 |
| Agepha Pharma FZ LLC | 1 | $20 |
| Innovation Technologies Inc | 1 | $16 |
| Cook Medical LLC | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Stryker | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Medtronic | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,753 in reported general payments places this provider in the 60th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 360 | $408,647 |
| EntrestoSacubitril/Valsartan | 183 | $220,823 |
| FarxigaDapagliflozin Propanediol | 144 | $160,806 |
| XareltoRivaroxaban | 101 | $112,196 |
| Repatha SureclickEvolocumab | 89 | $82,425 |
| JardianceEmpagliflozin | 65 | $70,136 |
| MultaqDronedarone Hcl | 25 | $48,733 |
| OzempicSemaglutide | 33 | $33,711 |
| JanuviaSitagliptin Phosphate | 19 | $23,042 |
| VascepaIcosapent Ethyl | 26 | $20,549 |
| BrilintaTicagrelor | 20 | $17,184 |
| Repatha PushtronexEvolocumab | 11 | $12,553 |
| CorlanorIvabradine Hcl | 20 | $10,996 |
| Metoprolol Succinate | 712 | $10,907 |
| Carvedilol ErCarvedilol Phosphate | 23 | $7,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $422 | $408,647360 claims |
| NovartisEntresto | $514 | $220,823183 claims |
| AstraZenecaFarxiga, Brilinta | $75 | $177,991164 claims |
| Johnson & JohnsonXarelto | $107 | $112,196101 claims |
| Boehringer IngelheimJardiance | $13 | $70,13665 claims |
| Sanofi-aventis U.S. LLCMultaq | $125 | $48,73325 claims |
| Novo NordiskOzempic | $81 | $33,71133 claims |
| MerckJanuvia | $210 | $23,04219 claims |
| AmgenCorlanor | $224 | $10,99620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Austin
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.